NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF/KRAS are enriched for targetable kinase fusions

(2019) Emiliano Cocco et al.   CANCER RESEARCH

High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden

(2019) Ryma Benayed et al.   CLINICAL CANCER RESEARCH

Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors

(2018) Erin R. Rudzinski et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Primary and Metastatic Melanoma With NTRK Fusions

(2018) Cecilia Lezcano et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma

(2018) Sarah Chiang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins

(2018) Ed S. Kheder et al.   CLINICAL CANCER RESEARCH

Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas

(2018) Sherise D Ferguson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment

(2018) Tao Xu et al.   Translational Oncology

Molecular characterization of cancers with NTRK gene fusions

(2018) Zoran Gatalica et al.   MODERN PATHOLOGY

NTRK fusion-positive cancers and TRK inhibitor therapy

(2018) Emiliano Cocco et al.   Nature Reviews Clinical Oncology

Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms

(2017) Lu Wang et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

(2017) Filippo Pietrantonio et al.   JNCI-Journal of the National Cancer Institute

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

(2017) Alexander Drilon et al.   Cancer Discovery

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

(2017) Filippo Pietrantonio et al.   JNCI-Journal of the National Cancer Institute

ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors

(2016) Ali H. Alassiri et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors

(2015) Shaobo Zhu et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Anchored multiplex PCR for targeted next-generation sequencing

(2014) Zongli Zheng et al.   NATURE MEDICINE

TRKing Down an Old Oncogene in a New Era of Targeted Therapy

(2014) Aria Vaishnavi et al.   Cancer Discovery

ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer

(2013) Rebecca J. Leeman-Neill et al.   CANCER

Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers

(2013) Julio C. Ricarte-Filho et al.   JOURNAL OF CLINICAL INVESTIGATION

Secretory Breast Carcinoma: Unique, Triple-Negative Carcinoma With a Favorable Prognosis and Characteristic Molecular Expression

(2011) Pooja Vasudev et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Rearrangements of NTRK1 gene in papillary thyroid carcinoma

(2009) A. Greco et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY